关键词:
Chromosome 1
Mutational profile
Myelodysplastic neoplasms
Prognosis
摘要:
目的: 分析伴1号染色体异常的骨髓增生异常肿瘤(MDS)患者临床和实验室特征及预后。 方法: 收集2016年8月至2024年6月于中国医学科学院血液病医院确诊的1 498例MDS初治患者病例资料,回顾性分析伴1号染色体异常的MDS患者临床特征、分子学等实验室特征以及总生存(OS)情况。 结果: 伴1号染色体异常患者共128例(8.54%),其中1q三体最为常见(85例,66.4%)。非1q三体患者较1q三体患者的骨髓原始细胞比例(5.0%对2.5%,P=0.030)、TP53突变检出率(30.2%对12.9%,P=0.033)及TP53中位等位基因突变频率(VAF)(46.7%对19.7%,P=0.034)均显著增高。伴1号染色体异常患者的OS时间[29(95% CI:17~41)个月]与不伴1号染色体异常患者[34(95% CI:25~43)个月]相比差异无统计学意义(P=0.800)。伴1号染色体异常患者中,1q三体与非1q三体两组患者中位OS时间分别为58(95% CI:24~107)个月和10(95% CI:5~15)个月,差异有统计学意义(P=0.005)。多因素分析示,原始细胞增多(IB)(HR=2.23,95% CI:1.10~4.54,P=0.027)、SF3B1突变(HR=5.61,95% CI:2.06~15.29,P=0.001)是影响伴1号染色体异常MDS患者生存的独立不良预后因素。 结论: 伴1号染色体异常的MDS患者中,1q三体与低原始细胞和低TP53突变检出率及VAF值相关,1q三体组OS时间显著延长。IB、SF3B1突变是影响伴1号染色体异常MDS患者生存的独立不良预后因素。.;Objective: To characterize the clinical and molecular features and evaluate the prognostic outcomes of patients with myelodysplastic neoplasms (MDS) with chromosome 1 abnormalities. Methods: We retrospectively analyzed 1 498 newly diagnosed MDS patients treated at the Institute of Hematology, Chinese Academy of Medical Sciences from August 2016 to June 2024. The clinical features, molecular characteristics, and overall survival (OS) of patients with chromosome 1 abnormalities were analyzed. Results: Chromosome 1 abnormalities were identified in 128 patients (8.54%), with 1q trisomy representing the most frequent cytogenetic alteration (85 cases, 66.4%). Compared to 1q trisomy patients, non-1q trisomy patients demonstrated significantly higher bone marrow blast percentages (5.0% vs 2.5%, P=0.030), TP53 mutation rates (30.2% vs 12.9%, P=0.033), and median TP53 variant allele frequencies (VAF) (46.7% vs 19.7%, P=0.034). No significant difference in OS was observed between patients with and without chromosome 1 abnormalities [29 (95% CI: 17-41) months vs 34 (95%CI: 25-43), P=0.800]. However, among patients with chromosome 1 abnormalities, the 1q trisomy patients showed markedly superior median OS compared to the non-1q trisomy patients [58 (95% CI: 24-107) vs 10 (95%